Yes not much Arrow shareholders can do, except the following. Not sure how much affect it will have on the proposed merger, but I would suggest the following:
1) Vote against a change in name from Arrow Pharmaceuticals to Sigma Pharmaceuticals, or similar
2) Vote against an increase in non-executive directors fees
3) Don't approve the issue of 550k of options and 4.4mill performance rights to De Alwis.
Probably be more of a hindrance than anything if the above was successful. I still can't believe that AWP have agreed to this price. Must be a whole lot in it for the management of AWP.
AWP
arrow pharmaceuticals limited
